Investor Presentaiton
US Mesh litigation - Overview of financial impact
P&L - overview of special items related to the Mesh
litigation
Balance
Assets
Restricted cash, DKKbn
Cash flow
Actual/Expected cash flow, DKKbn
Actual cash flow ☐ Expected cash flow
13/14-
17/18
18/19 19/20 20/21 21/22
YTD
22/23
0.5
0.5
EBIT (before
special items)
5,556
5,854
6,355 6,910
3,445
Special items
(Mesh)
-4,750
-400
-200
-300
Other special
items*
-171
-33
0.1
0.0
0.0
EBIT
5,156
5,854
6,155
6,439
3,412
0.0 0.0 0.0
14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 YTD
22/23
0.0
0.5
0.3
Liabilities
EBIT % (before
special items)
31
32
33
31
28
Total liability, DKKbn
EBIT %
29
32
32
32
29
28
Other payables
Provision
0.7
•
A total of DKK 6,150 million (DKK 5,650 million net of insurance coverage) has
been provisioned and is considered sufficient
•
Currently around 99% of known cases against Coloplast have been resolved
2.4
3.3
* DKK 171 million in special items related to the Atos Medical acquisition (transaction and integration
costs) in FY 2021/22. DKK 33 million in special items related to integration costs for the Atos Medical
acquisition in H1 2022/23.
63
1.2
0.1
0.1
0.3
1.1
0.4
0.3
0.5
0.1
0.3 0.2 0.2 0.0
0.1
14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 YTD
22/23
1.8
1.6
22/23 &
beyond
0.3
0.5
0.4
0.2 0.2
0.2
0.1
13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 22/23
• Insurance coverage of DKK 500m
received in 2013/14 and 2014/15
ColoplastView entire presentation